ArticleNature communications2026
High-accuracy glycan de novo prediction for N- and O-linked glycopeptides across multiple fragmentation techniques.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
N- and O-glycosylation are structurally diverse post-translational modifications that affect a range of biological functions. Glycoproteomics faces substantial challenges, particularly in the analysis of O-glycans due to their diversity compared to that of N-glycans. In addition, tandem mass spectrometry data patterns exhibit variability between different fragmentation methods. Existing de novo algorithms often lack sensitivity and are limited to sceHCD fragmentation, restricting their practical application. To address these limitations, we introduce DeepGlycan, a deep-learning-based method for de novo glycopeptide sequencing that captures relationships between glycopeptide spectra and fragment ions from both N- and O-glycans. DeepGlycan achieves over 92% glycan recall and around 95% glycan precision on N-glycopeptide spectra generated using both sceHCD and EThcD. In addition, it enables O-glycan de novo sequencing without additional training. Beyond benchmarking, DeepGlycan identifies an O-glycopeptide in mouse heart tissue whose assignment is supported by exoglycosidase treatment and comparison with a synthetic standard.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.